Tharimmune (THAR) Competitors $6.05 +1.09 (+21.98%) Closing price 04:00 PM EasternExtended Trading$6.20 +0.15 (+2.48%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. ARTV, RPTX, ZIVO, MNOV, IMMX, INMB, ANL, GANX, GNTA, and CUEShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Artiva Biotherapeutics (ARTV), Repare Therapeutics (RPTX), ZIVO Bioscience (ZIVO), MediciNova (MNOV), Immix Biopharma (IMMX), INmune Bio (INMB), Adlai Nortye (ANL), Gain Therapeutics (GANX), Genenta Science (GNTA), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Artiva Biotherapeutics Repare Therapeutics ZIVO Bioscience MediciNova Immix Biopharma INmune Bio Adlai Nortye Gain Therapeutics Genenta Science Cue Biopharma Tharimmune (NASDAQ:THAR) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Do analysts rate THAR or ARTV? Tharimmune currently has a consensus price target of $17.00, suggesting a potential upside of 180.99%. Artiva Biotherapeutics has a consensus price target of $17.00, suggesting a potential upside of 437.97%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of THAR or ARTV? 1.2% of Tharimmune shares are held by institutional investors. 10.0% of Tharimmune shares are held by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is THAR or ARTV more profitable? Artiva Biotherapeutics' return on equity of -42.60% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -1,239.20% -365.06% Artiva Biotherapeutics N/A -42.60%-37.76% Does the media prefer THAR or ARTV? In the previous week, Tharimmune had 8 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 11 mentions for Tharimmune and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.41 beat Tharimmune's score of 0.18 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, THAR or ARTV? Tharimmune has higher earnings, but lower revenue than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$12.20M-$6.10-0.99Artiva Biotherapeutics$250K308.80-$65.37MN/AN/A SummaryArtiva Biotherapeutics beats Tharimmune on 7 of the 12 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.04M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.9921.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book75.638.0710.026.67Net Income-$12.20M-$54.08M$3.27B$265.59M7 Day Performance21.73%2.26%3.17%3.42%1 Month Performance314.38%3.42%4.34%1.09%1 Year Performance107.90%18.61%44.11%23.85% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.4441 of 5 stars$6.05+22.0%$17.00+181.0%+68.1%$28.04MN/A-0.992High Trading VolumeARTVArtiva Biotherapeutics3.3304 of 5 stars$2.71-2.9%$17.00+527.3%-69.4%$66.21M$250K0.0081RPTXRepare Therapeutics2.8253 of 5 stars$1.54+0.3%$4.50+193.2%-45.5%$65.94M$53.48M-0.59180Positive NewsZIVOZIVO Bioscience0.2211 of 5 stars$17.20-4.7%N/A+72.6%$65.65M$15.85K-3.5210News CoverageGap DownMNOVMediciNova2.2282 of 5 stars$1.31+0.8%$7.00+434.4%-8.2%$64.25M$1M-5.2410Positive NewsAnalyst ForecastIMMXImmix Biopharma3.3455 of 5 stars$2.19flat$7.00+219.6%-10.1%$63.15MN/A-2.849Analyst DowngradeINMBINmune Bio2.0046 of 5 stars$2.36-1.7%$18.40+679.7%-71.0%$62.74M$50K-0.9510ANLAdlai Nortye1.6454 of 5 stars$1.70-0.3%$9.00+431.0%-43.5%$62.55MN/A0.00127GANXGain Therapeutics2.1818 of 5 stars$1.73+2.4%$7.80+350.9%+42.0%$62.19MN/A-2.7520News CoverageAnalyst RevisionGNTAGenenta Science2.3549 of 5 stars$3.40-0.3%$25.00+635.5%-7.8%$62.17MN/A0.007News CoverageCUECue Biopharma2.5983 of 5 stars$0.81-0.9%N/A+13.8%$62.13M$9.29M-1.4460 Related Companies and Tools Related Companies Artiva Biotherapeutics Competitors Repare Therapeutics Competitors ZIVO Bioscience Competitors MediciNova Competitors Immix Biopharma Competitors INmune Bio Competitors Adlai Nortye Competitors Gain Therapeutics Competitors Genenta Science Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access